RC18 160mg

BIOLOGICAL3 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Multiple Sclerosis, Relapsing-RemittingPrimary IgA NephropathySystemic Myasthenia Gravis

Phase 2

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

CompletedNCT04291781

RemeGen Co., Ltd.Primary IgA Nephropathy

Start: 2020-04-13End: 2021-05-20Updated: 2024-09-19

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

CompletedNCT04302103

RemeGen Co., Ltd.Systemic Myasthenia Gravis

Start: 2020-07-07End: 2022-02-11Updated: 2026-05-27

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

TerminatedNCT04625153

RemeGen Co., Ltd.Multiple Sclerosis, Relapsing-Remitting

Start: 2021-05-13End: 2026-04-03Updated: 2026-04-13

Related Papers

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations

Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study

CNS Neuroscience & Therapeutics2022-07-1831 citations